Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brai
Glucosamine, a widely used dietary supplement for joint health, has been linked to a faster progression of Alzheimer's disease in a recent large-scale health-record analysis. The study found that individuals taking glucosamine were 25% more likely to experience a progression from mild cognitive impairment to dementia. This association raises concerns about the potential risks of glucosamine supplementation, particularly for individuals with a high risk of developing Alzheimer's.
The potential mechanism underlying this association is rooted in the biochemical processes involved in Alzheimer's disease. Lab experiments suggest that glucosamine may intensify an abnormal sugar-tagging process in the Alzheimer's brain, which could contribute to the accelerated disease progression. This finding is particularly noteworthy given the widespread use of glucosamine supplements and the ongoing search for effective treatments for Alzheimer's.
As the search for effective Alzheimer's treatments continues, it is essential to carefully evaluate the potential risks and benefits of commonly used supplements like glucosamine. Clinicians and researchers should prioritize further investigation into the relationship between glucosamine use and Alzheimer's progression, including large-scale clinical trials to confirm these findings. Additionally, individuals considering glucosamine supplementation, especially those with a family history of Alzheimer's or existing cognitive impairment, should consult with their healthcare providers to weigh the potential risks and benefits.
Originally reported by sciencedaily.com. LearningWire adds analysis for science & discovery readers.